216 related articles for article (PubMed ID: 18470919)
1. Hirudin versus heparin for use in whole blood in vitro biocompatibility models.
Bexborn F; Engberg AE; Sandholm K; Mollnes TE; Hong J; Nilsson Ekdahl K
J Biomed Mater Res A; 2009 Jun; 89(4):951-9. PubMed ID: 18470919
[TBL] [Abstract][Full Text] [Related]
2. The effect of r-hirudin vs. heparin on blood-membrane interactions during hemodialysis.
van Wyk V; Badenhorst PN; Kotzé HF
Clin Nephrol; 1997 Dec; 48(6):381-7. PubMed ID: 9438098
[TBL] [Abstract][Full Text] [Related]
3. Artificial surface-induced cytokine synthesis: effect of heparin coating and complement inhibition.
Lappegård KT; Fung M; Bergseth G; Riesenfeld J; Mollnes TE
Ann Thorac Surg; 2004 Jul; 78(1):38-44; discussion 44-5. PubMed ID: 15223398
[TBL] [Abstract][Full Text] [Related]
4. Effect of complement inhibition and heparin coating on artificial surface-induced leukocyte and platelet activation.
Lappegård KT; Fung M; Bergseth G; Riesenfeld J; Lambris JD; Videm V; Mollnes TE
Ann Thorac Surg; 2004 Mar; 77(3):932-41. PubMed ID: 14992902
[TBL] [Abstract][Full Text] [Related]
5. Extracorporeal circulation: in vivo and in vitro analysis of complement activation by heparin-bonded surfaces.
Kirschfink M; Kovacs B; Mottaghy K
Circ Shock; 1993 Jul; 40(3):221-6. PubMed ID: 8348684
[TBL] [Abstract][Full Text] [Related]
6. A new in vitro model to study interaction between whole blood and biomaterials. Studies of platelet and coagulation activation and the effect of aspirin.
Hong J; Nilsson Ekdahl K; Reynolds H; Larsson R; Nilsson B
Biomaterials; 1999 Apr; 20(7):603-11. PubMed ID: 10208402
[TBL] [Abstract][Full Text] [Related]
7. The ability of surface characteristics of materials to trigger leukocyte tissue factor expression.
Fischer M; Sperling C; Tengvall P; Werner C
Biomaterials; 2010 Mar; 31(9):2498-507. PubMed ID: 20035991
[TBL] [Abstract][Full Text] [Related]
8. Effect of hirudin versus heparin on hemocompatibility of blood contacting biomaterials: an in vitro study.
Kopp R; Bernsberg R; Kashefi A; Mottaghy K; Rossaint R; Kuhlen R
Int J Artif Organs; 2005 Dec; 28(12):1272-7. PubMed ID: 16404704
[TBL] [Abstract][Full Text] [Related]
9. Time sequence of blood activation by nanoporous alumina: Studies on platelets and complement system.
Ferraz N; Ott MK; Hong J
Microsc Res Tech; 2010 Dec; 73(12):1101-9. PubMed ID: 20232464
[TBL] [Abstract][Full Text] [Related]
10. In vitro blood reactivity to hydroxylated and non-hydroxylated polymer surfaces.
Sperling C; Maitz MF; Talkenberger S; Gouzy MF; Groth T; Werner C
Biomaterials; 2007 Sep; 28(25):3617-25. PubMed ID: 17524475
[TBL] [Abstract][Full Text] [Related]
11. Complement activation and bioincompatibility. The terminal complement complex for evaluation and surface modification with heparin for improvement of biomaterials.
Mollnes TE; Videm V; Riesenfeld J; Garred P; Svennevig JL; Fosse E; Hogasen K; Harboe M
Clin Exp Immunol; 1991 Oct; 86 Suppl 1(Suppl 1):21-6. PubMed ID: 1934602
[TBL] [Abstract][Full Text] [Related]
12. Biological relevance of anti-recombinant hirudin antibodies--results from in vitro and in vivo studies.
Liebe V; Brückmann M; Fischer KG; Haase KK; Borggrefe M; Huhle G
Semin Thromb Hemost; 2002 Oct; 28(5):483-90. PubMed ID: 12420244
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of complement activation by soluble recombinant CR1 under conditions resembling those in a cardiopulmonary circuit: reduced up-regulation of CD11b and complete abrogation of binding of PMNs to the biomaterial surface.
Larsson R; Elgue G; Larsson A; Ekdahl KN; Nilsson UR; Nilsson B
Immunopharmacology; 1997 Dec; 38(1-2):119-27. PubMed ID: 9476123
[TBL] [Abstract][Full Text] [Related]
14. In vitro assessment of blood compatibility: residual and dynamic markers of cellular activation.
Johnson G; Curry B; Cahalan L; Prater R; Beeler M; Gartner M; Biggerstaff J; Cahalan P
J Biomater Appl; 2013 May; 27(8):925-36. PubMed ID: 22210807
[TBL] [Abstract][Full Text] [Related]
15. Complement activation in prestorage leucocyte-filtered plasma.
Hyllner M; Tylman M; Bengtson JP; Rydberg L; Bengtsson A
Transfus Med; 2004 Feb; 14(1):45-52. PubMed ID: 15043593
[TBL] [Abstract][Full Text] [Related]
16. Detection of surface bound complement at increasing serum anticoagulant concentrations.
Arvidsson S; Askendal A; Lindahl TL; Tengvall P
Colloids Surf B Biointerfaces; 2008 Apr; 62(2):214-9. PubMed ID: 18006286
[TBL] [Abstract][Full Text] [Related]
17. A new model for evaluation of biocompatibility: combined determination of neoepitopes in blood and on artificial surfaces demonstrates reduced complement activation by immobilization of heparin.
Mollnes TE; Riesenfeld J; Garred P; Nordström E; Høgåsen K; Fosse E; Götze O; Harboe M
Artif Organs; 1995 Sep; 19(9):909-17. PubMed ID: 8687297
[TBL] [Abstract][Full Text] [Related]
18. Material-specific thrombin generation following contact between metal surfaces and whole blood.
Hong J; Azens A; Ekdahl KN; Granqvist CG; Nilsson B
Biomaterials; 2005 Apr; 26(12):1397-403. PubMed ID: 15482827
[TBL] [Abstract][Full Text] [Related]
19. Activation of neutrophil granulocytes in an in vitro model of a cardiopulmonary bypass.
Asberg AE; Videm V
Artif Organs; 2005 Dec; 29(12):927-36. PubMed ID: 16305648
[TBL] [Abstract][Full Text] [Related]
20. APT070 inhibits complement activation during in vitro cardiopulmonary bypass.
De Silva RJ; Vuylsteke A; Fritchley SJ; Trull AK; Dunning JJ; Wallwork J
Eur J Cardiothorac Surg; 2006 Jul; 30(1):72-6. PubMed ID: 16723247
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
